CV6 Therapeutics, a Belfast, UK-based drug development biotechnology company, raised $9.2M in funding.
Backers included QUBIS, Invest Northern Ireland, CoFund NI, and Techstart Ventures.
The company intends to use the funds to progress its oncology asset CV6-168 into a Phase 1a clinical trial and perform further scientific development work.
Led by CEO Dr Robert Ladner, CV6 Therapeutics is a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and inflammatory diseases. Oncology drug candidate CV6-168 has completed all pre-clinical development milestones.
The company plans to start a first-in-human phase 1a clinical trial of CV6-168 in advanced cancers in 2023. Inflammatory disease asset CV6-1271 is in preclinical-development. Cancer cell DNA uracilation by CV6-168 is aided by combination with standard cancer therapies such as thymidylate synthase (TS) inhibitors and results in uracil-based DNA damage and cell death while simultaneously stimulating the immune system to further enhance the anticancer effect.
FinSMEs
03/11/2022